Archived Facts

Posts Tagged ‘Genome’

LONDON/NEW YORK (Reuters) – GlaxoSmithKline is holding talks this weekend with Human Genome Sciences to agree a deal to acquire it for some $ 2.6 billion, after pursuing the U.S. biotech company for three months, sources familiar with the situation said on Sunday.

Incoming search terms:

Related Posts:

GlaxoSmithKline PLC said Friday it has again extended its $ 2.6 billion hostile offer for shares of Human Genome Sciences Inc., its collaborator on the lupus drug Benlysta.

Related Posts:

(Reuters) – Human Genome Sciences Inc said on Thursday it had adopted a stockholder rights plan as the biotechnology company defends itself against a $ 2.6 billion hostile takeover bid by drugmaker GlaxoSmithKline Plc.

Incoming search terms:

Related Posts:

LONDON (Reuters) – GlaxoSmithKline is to take its unsolicited $ 2.6 billion takeover bid for Human Genome Sciences direct to shareholders in the U.S. biotech group by launching a tender offer at $ 13 a share this week.

Related Posts:

LONDON (Reuters) – Human Genome Sciences Inc said on Thursday its long-time partner GlaxoSmithKline Plc had made an unsolicited proposal to buy it for $ 13.00 per share in cash, a move underscoring the rapid pace of deal-making in pharmaceuticals.

Related Posts:

LONDON (Reuters) – Human Genome Sciences Inc said on Thursday its long-time partner GlaxoSmithKline Plc had made an unsolicited proposal to buy it for $ 13.00 per share in cash, a move underscoring the rapid pace of deal-making in pharmaceuticals.

Related Posts:

Human Genome Sciences Inc. reported a larger second-quarter loss on Thursday as it recorded higher expenses related to its lupus drug Benlysta and lower revenue compared to the year-ago period when it received payments related to an agreement with Novartis AG.

Related Posts:

Drug developer Human Genome Sciences Inc. reported a larger fourth-quarter loss on Thursday as expenses related to its lupus drug candidate Benlysta grew, and revenue decreased.
All News, Video and Posts related to SECTOR: Health Care

Related Posts:

Scientists should dial down expectations about breakthroughs from mapping the human genome because it will take years to make sense of all the information, a leader of the mapping project says.
All News, Video and Posts related to SECTOR: Health Care

Related Posts:

Regulators should reach a decision by early December on an experimental lupus drug made by Human Genome Sciences and GlaxoSmithKline, the companies said Thursday.

More:
Potential lupus drug gets FDA priority review

Related Posts: